HC Wainwright Brokers Lower Earnings Estimates for GLSI

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2025 EPS estimates for shares of Greenwich LifeSciences in a research report issued to clients and investors on Monday, April 21st. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.24) per share for the quarter, down from their prior estimate of ($0.21). HC Wainwright has a "Buy" rating and a $39.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Greenwich LifeSciences' Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.94) EPS.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.40).

Greenwich LifeSciences Price Performance

Shares of GLSI stock traded down $0.18 during trading hours on Wednesday, reaching $9.80. 8,374 shares of the company's stock were exchanged, compared to its average volume of 45,269. The company's 50 day moving average is $10.63 and its two-hundred day moving average is $12.23. The company has a market cap of $130.09 million, a P/E ratio of -12.26 and a beta of 1.76. Greenwich LifeSciences has a 1 year low of $8.06 and a 1 year high of $18.75.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after buying an additional 5,861 shares during the period. Northern Trust Corp boosted its stake in shares of Greenwich LifeSciences by 17.3% during the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company's stock worth $982,000 after acquiring an additional 12,923 shares in the last quarter. State Street Corp grew its holdings in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after acquiring an additional 3,005 shares during the period. Garden State Investment Advisory Services LLC purchased a new position in Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. Finally, Rhumbline Advisers boosted its position in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after purchasing an additional 3,168 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company's stock.

Insider Buying and Selling

In other Greenwich LifeSciences news, CEO Snehal Patel bought 3,600 shares of Greenwich LifeSciences stock in a transaction on Monday, April 7th. The stock was bought at an average price of $9.10 per share, with a total value of $32,760.00. Following the completion of the acquisition, the chief executive officer now owns 5,561,602 shares in the company, valued at $50,610,578.20. The trade was a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 14,500 shares of company stock valued at $129,267 over the last quarter. Company insiders own 51.67% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.